Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Cerebrotendinous xanthomatosis Indication Strategy Report 2026: CYP27A1, Trials and Deals
24 July 2026
2026 Cerebrotendinous xanthomatosis strategy: epidemiology, CYP27A1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Lysinuric protein intolerance Indication Strategy Report 2026: SLC7A7, Trials and Deals
24 July 2026
2026 Lysinuric protein intolerance strategy: epidemiology, SLC7A7 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Cystinuria Indication Strategy Report 2026: SLC3A1, Trials and Deals
24 July 2026
2026 Cystinuria strategy: epidemiology, SLC3A1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Methylglutaconic aciduria Indication Strategy Report 2026: TAZ, Trials and Deals
24 July 2026
2026 Methylglutaconic aciduria strategy: epidemiology, TAZ biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Hartnup disease Indication Strategy Report 2026: SLC6A19, Trials and Deals
24 July 2026
2026 Hartnup disease strategy: epidemiology, SLC6A19 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
3-methylcrotonyl-CoA carboxylase deficiency Indication Strategy Report 2026: MCCC1, Trials and Deals
24 July 2026
2026 3-methylcrotonyl-CoA carboxylase deficiency strategy: epidemiology, MCCC1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
HMG-CoA lyase deficiency Indication Strategy Report 2026: HMGCL, Trials and Deals
24 July 2026
2026 HMG-CoA lyase deficiency strategy: epidemiology, HMGCL biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Holocarboxylase synthetase deficiency Indication Strategy Report 2026: HLCS, Trials and Deals
24 July 2026
2026 Holocarboxylase synthetase deficiency strategy: epidemiology, HLCS biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
NGLY1 deficiency Indication Strategy Report 2026: NGLY1, Trials and Deals
24 July 2026
2026 NGLY1 deficiency strategy: epidemiology, NGLY1 biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
MPI-congenital disorder of glycosylation Indication Strategy Report 2026: MPI, Trials and Deals
24 July 2026
2026 MPI-congenital disorder of glycosylation strategy: epidemiology, MPI biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type XV Indication Strategy Report 2026: GYG1, Trials and Deals
24 July 2026
2026 Glycogen storage disease type XV strategy: epidemiology, GYG1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Glycogen storage disease type XIII Indication Strategy Report 2026: ENO3, Trials and Deals
24 July 2026
2026 Glycogen storage disease type XIII strategy: epidemiology, ENO3 biology, clinical competition, recent deals, unmet need and market attractiveness.